KRAS and neoplasm: In NSCLC and colorectal cancers (CRC), the KRas mutation has been linked to an increased expression in PD-L1, an immune checkpoint protein expressed in tumor cells that interacts with the PL1 receptor on T-cells as a method of avoiding immune-mediated cell death [269,270].